IL6 and type 2 diabetes mellitus: In the present study, we found that metformin treatment has specific effects on cytokines (serum IL-6 and urinary MCP-1) as compared to the non-metformin (i.e., gliclazide, acarbose, or repaglinide) treatment type 2 diabetic patients.